Procyrion Welcomes Lucas Buchanan to Its Board of Directors
Procyrion™, Inc., a medical device company dedicated to enhancing outcomes for patients with cardiac and renal issues, has made an important announcement: Lucas Buchanan has joined its Board of Directors. Mr. Buchanan brings extensive experience in the MedTech industry, particularly in areas such as commercialization, operations, business development, and finance.
The Value of Lucas's Experience
Bringing on a seasoned executive like Lucas Buchanan is a significant advantage for Procyrion. His previous roles as Chief Operating Officer and Chief Financial Officer at Silk Road Medical give him a unique perspective that will help advance the company's mission to provide innovative medical technologies to patients in need. Lucas's expertise will be crucial as Procyrion continues to develop its flagship product, the Aortix therapy.
Commitment to the DRAIN-HF Trial
Procyrion remains focused on its commitment to the DRAIN-HF pivotal IDE trial, a vital step in preparing for the U.S. commercialization of the Aortix device. This cutting-edge percutaneous mechanical circulatory support (pMCS) technology aims to enhance kidney perfusion while relieving the heart, marking a significant advancement in treating patients with acute decompensated heart failure.
Achievements and Future Goals
Lucas's past achievements and strategic vision are expected to strengthen the regulatory and clinical pathways for Procyrion, especially as the company prepares to commercialize its technology. The Aortix device specifically targets a challenging patient population: those suffering from cardiorenal syndrome who have not responded to conventional therapies.
Mr. Buchanan’s Background and Expertise
Before his time at Silk Road Medical, Lucas gained valuable experience in various roles at other prominent companies, including Medtronic and Ernst & Young. He also serves on the Board of Directors for Endologix and plays a key advisory role for CRG LP. Academically, he holds a BA in Economics from Duke University and an MBA in Health Care Management from The Wharton School at the University of Pennsylvania.
A Promising Treatment Option
The Aortix device is an advanced catheter-deployed pump that operates without a valve, utilizing fluid entrainment to effectively move blood. This innovative approach provides therapeutic benefits, particularly for patients experiencing congestion despite existing medical therapies. The project reflects Procyrion's commitment to addressing the clinical challenges faced by those with acute decompensated heart failure.
Future Directions for Procyrion
As Procyrion moves forward, the company is well-positioned to utilize Lucas's insights into commercialization and healthcare strategy, particularly as they work to complete patient enrollment in the DRAIN-HF trial. His involvement is crucial as the company prepares to introduce the Aortix pump to the market.
About Procyrion
Procyrion™, Inc. is committed to offering effective treatment options for patients dealing with cardiac and renal impairment. The ongoing development of the Aortix™ device showcases the company's dedication to addressing significant unmet medical needs. Currently, the device is investigational and not yet approved for general sale. For more information about Procyrion and its innovative solutions, please visit their official website.
Frequently Asked Questions
What is Procyrion, Inc.?
Procyrion, Inc. is a medical device company focused on providing treatment options for patients with cardiac and renal impairment using innovative technologies.
What role does Lucas Buchanan play in Procyrion?
Lucas Buchanan has been appointed to the Board of Directors and brings expertise in MedTech and business development to help guide the company's strategic direction.
What is the Aortix device?
The Aortix device is a catheter-based pump that aims to enhance kidney perfusion and unload the heart for patients with acute decompensated heart failure.
What is the DRAIN-HF pivotal IDE trial?
The DRAIN-HF pivotal IDE trial is a crucial study designed to evaluate the effectiveness of the Aortix pump in treating patients with cardiorenal syndrome.
How does the Aortix device work?
The Aortix device uses fluid entrainment to pump blood naturally, providing therapeutic benefits without requiring a valve, catering specifically to patients resistant to standard treatments.
